JP2024540147A - サルベコウイルスに対するモノクローナル抗体の中和 - Google Patents

サルベコウイルスに対するモノクローナル抗体の中和 Download PDF

Info

Publication number
JP2024540147A
JP2024540147A JP2024525544A JP2024525544A JP2024540147A JP 2024540147 A JP2024540147 A JP 2024540147A JP 2024525544 A JP2024525544 A JP 2024525544A JP 2024525544 A JP2024525544 A JP 2024525544A JP 2024540147 A JP2024540147 A JP 2024540147A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain variable
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540147A5 (cg-RX-API-DMAC7.html
Inventor
マンチーニ、ニカシオ
クレメンティ、ニコラ
クレメンティ、マッシモ
クリスクオロ、エレナ
システィ、ソフィア
リベラ、マルティーナ
Original Assignee
オスペダーレ サン ラファエレ エス.アール.エル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オスペダーレ サン ラファエレ エス.アール.エル filed Critical オスペダーレ サン ラファエレ エス.アール.エル
Publication of JP2024540147A publication Critical patent/JP2024540147A/ja
Publication of JP2024540147A5 publication Critical patent/JP2024540147A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024525544A 2021-10-29 2022-07-20 サルベコウイルスに対するモノクローナル抗体の中和 Pending JP2024540147A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21205626.1 2021-10-29
EP21205626.1A EP4174083A1 (en) 2021-10-29 2021-10-29 Neutralizing monoclonal antibodies against sarbecoviruses
PCT/IB2022/056706 WO2023073441A1 (en) 2021-10-29 2022-07-20 Neutralizing monoclonal antibodies against sarbecoviruses

Publications (2)

Publication Number Publication Date
JP2024540147A true JP2024540147A (ja) 2024-10-31
JP2024540147A5 JP2024540147A5 (cg-RX-API-DMAC7.html) 2025-07-31

Family

ID=78414544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525544A Pending JP2024540147A (ja) 2021-10-29 2022-07-20 サルベコウイルスに対するモノクローナル抗体の中和

Country Status (7)

Country Link
US (1) US20260234220A1 (cg-RX-API-DMAC7.html)
EP (2) EP4174083A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024540147A (cg-RX-API-DMAC7.html)
AU (1) AU2022374853A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235310A1 (cg-RX-API-DMAC7.html)
IL (1) IL312392A (cg-RX-API-DMAC7.html)
WO (1) WO2023073441A1 (cg-RX-API-DMAC7.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021173753A1 (en) * 2020-02-26 2021-09-02 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
WO2021207152A1 (en) * 2020-04-06 2021-10-14 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021173753A1 (en) * 2020-02-26 2021-09-02 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
WO2021207152A1 (en) * 2020-04-06 2021-10-14 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCIENCE TRANSLATIONAL MEDICINE, vol. 13, no. 616, JPN6026016331, 20 October 2021 (2021-10-20), ISSN: 0005849988 *

Also Published As

Publication number Publication date
IL312392A (en) 2024-06-01
WO2023073441A1 (en) 2023-05-04
EP4174083A1 (en) 2023-05-03
EP4423124A1 (en) 2024-09-04
AU2022374853A1 (en) 2024-05-16
US20260234220A1 (en) 2026-08-13
CA3235310A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
Gai et al. A potent neutralizing nanobody against SARS‐CoV‐2 with inhaled delivery potential
CN111647076B (zh) 抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用
AU2013229488B2 (en) Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
Collarini et al. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients
CN110684102B (zh) 一种sftsv检测试剂盒
Khan et al. Cross-neutralizing anti-HIV-1 human single chain variable fragments (scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library
US20240182549A1 (en) Peptides and antibody fusions that bind to sars-cov-2 and methods of using same
CN115515976A (zh) 冠状病毒抗体
WO2025246679A1 (zh) 一种广谱中和冠状病毒的抗体及其应用
JP2013505236A (ja) Hiv−1抗体
Chen et al. Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants
JP2008532559A (ja) ウイルス感染の治療及び予防又は治療及び予防の改善
WO2021105669A1 (en) Antibodies
CN103224559B (zh) 人源hiv广谱中和抗体a16及其相关生物材料与应用
AU2005302416A1 (en) Broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies
Pavan et al. Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants
EP4174083A1 (en) Neutralizing monoclonal antibodies against sarbecoviruses
CN102190726B (zh) 一种人源HIV抗体的Fab片段及其编码基因与应用
US20240166727A1 (en) Human neutralizing antigen specific proteins for spike-rbd of sars-cov-2
Li et al. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies
CN101198374B (zh) 具有抗hiv中和活性的抗体或其片段
CN107383190A (zh) 人源抗HIVgp41特异性抗体及其应用
TW202346329A (zh) 冠狀病毒之特異性抗體及其用途
IL278955A (en) Antibodies against sars cov-2
CN121335920A (zh) 靶向HIV Env上的CD4结合位点的广谱中和抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428